Filtricine
Filtricine, Inc. is a clinical-stage biotechnology company based in the San Francisco Bay Area, focused on developing innovative medical food products that target cancer metabolism. Backed by venture capital, the company leverages research from Stanford University to create nutritionally complete, amino‑acid‑restricted meals designed to starve cancer cells while preserving patient health. Their lead product, Tality, is currently being evaluated in clinical trials for prostate cancer and other solid tumors, aiming to improve outcomes and quality of life for patients worldwide.
Filtricine is profiled on the APIs.io network. Tagged areas include Biotechnology, Cancer, Medical-Food, Clinical-Trials, and San-Francisco.
Filtricine’s developer surface includes support, engineering blog, signup flow, and 6 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Filtricine Rate Limits
RATE LIMITSSecurity Posture 2
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Scopes 1
OAuth scopes governing access to this provider's APIs.
Resources
Get Started 1
Portal, sign-up, and the first successful call
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 2
The organization behind the API
Other 2
Properties that don't map to a standard resource type
Source (apis.yml)
Filtricine API — frequently asked questions
How do I authenticate with the Filtricine API?
Filtricine documents its authentication (0 schemes). The details are profiled on APIs.io as Filtricine Authentication.
Is the Filtricine API ready for AI agents?
Filtricine has a Kin Score of 14.9 out of 100 (emerging) and an Agent Readiness score of 2.5 (human-only), scored by API Evangelist on 2026-10-31.
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.